Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 32, Issue 11, 2013, Pages 1427-1435

  Di Lello, F A ^a   Caruz, A ^b   Rallon, N I ^c   Rivero Juarez, A ^d   Neukam, K ^a   Barreiro, P ^c   Camacho, A ^d   Garcia Rey S ^a   Rivero, A ^d   Soriano, V ^c   Cifuentes, C ^a   Macias, J ^a   Pineda, J A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b UNIVERSITY OF JAÉN   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERLEUKIN 28B; LOW DENSITY LIPOPROTEIN RECEPTOR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GENETIC PATTERN; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IL28B GENE; LDLR GENE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGICAL RESPONSE; UNSPECIFIED SIDE EFFECT; VIRAL CLEARANCE; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERONS; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, LDL; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84886592009     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-013-1894-9     Document Type: Article

References (30)

1. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401
2. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109
3. Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, Camacho A et al (2010) Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 51:788-795
4. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C et al (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798-801
5. Barreiro P, Pineda JA, Rallón N, Naggie S, Martín-Carbonero L, Neukam K et al (2011) Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. J Infect Dis 203:1629-1636
6. Labarga P, Soriano V, Caruz A, Poveda E, Di Lello F, Hernandez-Quero J et al (2011) Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. AIDS 25:761-766
7. Aghemo A, Marabita F, De Nicola S, Rumi MG, Cheroni C, Scavelli R et al (2011) Fibrosis progression in patients with chronic hepatitis C is not influenced by IL28B polymorphisms. J Hepatol 54(Suppl 1):S519
8. Fornasiere E, Cmet S, Bitetto D, Cussigh A, Fumolo E, Bignulin S et al (2011) Interleukin 28B rs12979860 C/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. J Hepatol 54(Suppl 1):S456-S457
9. Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A et al (2010) Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 51:1904-1911
10. del Valle J, Mira JA, de los Santos I, López-Cortés LF, Merino D, Rivero A et al (2008) Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients. AIDS 22:923-930
11. Harrison SA, Rossaro L, Hu K-Q, Patel K, Tillmann H, Dhaliwal S et al (2010) Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 52:864-874
12. Muallem H, North KE, Kakoki M, Wojczynski MK, Li X, Grove M et al (2007) Quantitative effects of common genetic variations in the 3′UTR of the human LDL-receptor gene and their associations with plasma lipid levels in the Atherosclerosis Risk in Communities study. Hum Genet 121:421-431
13. Petit JM, Minello A, Duvillard L, Jooste V, Monier S, Texier V et al (2007) Cell surface expression of LDL receptor in chronic hepatitis C: correlation with viral load. Am J Physiol Endocrinol Metab 293:416-420
14. Hennig BJW, Hellier S, Frodsham AJ, Zhang L, Klenerman P, Knapp S et al (2002) Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection. Genes Immun 3:359-367
15. Mas Marques A, Mueller T, Welke J, Taube S, Sarrazin C, Wiese M et al (2009) Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection. Infect Genet Evol 9:847-852
16. Pineda JA, Caruz A, Di Lello FA, Camacho A, Mesa P, Neukam K et al (2011) Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients. AIDS 25:1415-1420
17. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265
18. Scheuer PJ (1991) Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13:372-374
19. Nakahara M, Fujii H, Maloney PR, Shimizu M, Sato R (2002) Bile acids enhance low density lipoprotein receptor gene expression via a MAPK cascade-mediated stabilization of mRNA. J Biol Chem 277:37229-37234
20. Wilson GM, Vasa MZ, Deeley RG (1998) Stabilization and cytoskeletal-association of LDL receptor mRNA are mediated by distinct domains in its 3′ untranslated region. J Lipid Res 39:1025-1032
21. Enjoji M, Nakamuta M, Kinukawa N, Sugimoto R, Noguchi K, Tsuruta S et al (2000) Beta-lipoproteins influence the serum level of hepatitis C virus. Med Sci Monit 6:841-844
22. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD et al (2010) IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52:1888-1896
23. Molina S, Castet V, Fournier-Wirth C, Pichard-Garcia L, Avner R, Harats D et al (2007) The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol 46:411-419
24. Rallón NI, Soriano V, Naggie S, Restrepo C, Goldstein D, Vispo E et al (2011) IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. AIDS 25:1025-1033
25. Lin C-Y, Chen J-Y, Lin T-N, Jeng W-J, Huang C-H, Huang C-W et al (2011) IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One 6:e18322
26. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T et al (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138:1338-1345
27. di Iulio J, Ciuffi A, Fitzmaurice K, Kelleher D, Rotger M, Fellay J et al (2011) Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology 53:1446-1454
28. Nattermann J, Timm J, Nischalke HD, Olbrich A, Michalk M, Tillmann HL et al (2011) The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Δ32 mutation. J Hepatol 55:1201-1206
29. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH et al (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364:2405-2416
30. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS et al (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195-1206